Integra LifeSciences Holdings announced that it has entered into an exclusive worldwide license and development agreement with Stout Medical Group to develop and commercialise an expandable interbody device.
The license allows Integra to develop a device that surgeons could implant into the disc space using minimally invasive techniques, enabling them to perform a potentially safer, simpler procedure. During an interbody fusion procedure, this novel technology is designed to allow a surgeon to adjust the height in-situ according to the patient’s needs.
“The expandable interbody fusion platform is an important and innovative addition to our minimally invasive device portfolio,” said Brian Larkin, Integra’s president, Global Spine/Orthobiologics, and head of Strategic Development.
Tom Molz, president and CEO of Stout Medical Group commented, “Stout Medical Group strongly believes in working with its licensing partners in the development and commercialisation of its technologies. We are very excited to be working with Integra on the expandable interbody platform.”
